Efficacy and Safety of HMM1-022 in Temporary Correction of Crow's Feet

NCT ID: NCT06428253

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 171 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-14
• Study Completion Date: 2025-11-27

Brief Summary

The purpose of this study is to compare the efficacy and safety of HMM1-022 with Rejuran to improve Crow's feet

Detailed Description

A single center, subject & evaluator-blind, randomized, matched pairs, active-controlled, confirmatory study to evaluate the efficacy and safety of HMM1-022 in temporary correction of Crow's feet

Conditions

Crow's Feet

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

HMM1-022

Participants will receive injections into the wrinkles at the corners of each eye, up to 1 mL each, four times at two-week intervals.

Group Type: EXPERIMENTAL

HMM1-022

Intervention Type: DEVICE

intradermal injection

REJURAN®

Participants will receive injections into the wrinkles at the corners of each eye, up to 1 mL each, four times at two-week intervals.

Group Type: ACTIVE_COMPARATOR

HMM1-022

Intervention Type: DEVICE

intradermal injection

Interventions

HMM1-022

intradermal injection

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Adult aged 19 years or older
• Individuals who have voluntarily decided to participate in the clinical trial after receiving and understanding a detailed explanation, and who have provided written consent
• Individuals who have agreed to discontinue all dermatological treatments, including wrinkle treatments around the eyes, during the clinical trial period

Exclusion Criteria

1. Individuals with a history of anaphylaxis or severe allergic diseases that may affect the clinical trial

2. Individuals diagnosed with autoimmune diseases, sarcoid granulomatous pathology, or Osler's endocarditis

3. Individuals with hypersensitivity to the investigational medical device, its components (polynucleotide sodium, hyaluronic acid sodium, lidocaine), or other amide-type local anesthetics

4. Individuals with a history of bleeding disorders

5. Individuals with a history of facial nerve paralysis or ptosis

6. Individuals with significant facial asymmetry that may affect the clinical trial

7. Individuals with skin diseases, infections, or abnormalities such as scars in the eye area that could affect the clinical trial

8. Individuals with a history of keloid formation, hyperpigmentation, or hypertrophic scar in the evaluation area

9. Individuals with a history of malignant tumors within 5 years prior to Visit 1 (screening), except those with treated basal cell or squamous cell skin cancer not in the eye area, or treated cervical cancer

10. Individuals with clinically significant disorders or psychiatric conditions affecting the cardiovascular, gastrointestinal, respiratory, endocrine, immune, or central nervous systems, or those with conditions that may significantly impact the clinical trial

11. Individuals who have undergone or are scheduled to undergo treatments affecting the efficacy assessment of crow's feet wrinkles during the following periods:

• Within 24 months before Visit 1 (screening) using Poly(L-Lactide) or Poly(ε-Caprolactone) for wrinkle treatment
• Within 18 months before Visit 1 (screening) using Calcium hydroxylapatite (CaHA) for wrinkle treatment
• Within 12 months before Visit 1 (screening) using hyaluronic acid for wrinkle treatment
• Within 6 months before Visit 1 (screening) using collagen, botulinum toxin, or other wrinkle treatments
• Within 6 months before Visit 1 (screening) undergoing invasive laser, deep dermabrasion, or other procedures or surgeries related to wrinkle treatment in the eye area
• Insertion of permanent skin expansion implants like Softform or silicone in the eye area before screening
• Starting or receiving a new oral or topical anti-wrinkle medication with wrinkle prevention effects within 3 months before Visit 1 (screening)

12. Individuals who have undergone the following drug therapies that could affect the evaluation of the investigational medical device:

• Use of NSAIDs, antiplatelet agents, anticoagulants, immunosuppressants within 2 weeks before Visit 1 (screening), or required during the clinical trial period (excluding low-dose aspirin (100 mg, up to 300 mg/day))
• Use of topical agents (steroids, retinoids: only medications, not cosmetics) in the eye area within 1 month before Visit 1 (screening) or planned use during the clinical trial

13. Individuals who have received a COVID-19 vaccine within 3 weeks before the application of the investigational medical device or are planned to receive it within 4 weeks after application

14. Individuals with ongoing infectious diseases, including COVID-19, or suspected COVID-19 infection within 2 weeks before screening

15. Individuals who have been administered or undergone other investigational drugs or devices within 1 month before Visit 1 (screening), or within 6 months for studies related to crow's feet wrinkles

16. Individuals with positive results for viral tests (HBs Ag, HCV Ab, HIV Ab) performed at Visit 1 (screening) or within 1 month before screening

17. Individuals with a history of alcohol or drug addiction

18. Pregnant or breastfeeding women

19. Individuals planning to become pregnant during the clinical trial or those who, along with their partners (or spouses), do not agree to use medically acceptable contraception methods (examples include: hormonal contraceptives, proven failure rates intrauterine devices (IUDs), double barrier methods, sterilization)

20. Individuals deemed unsuitable for participation in the clinical trial based on the investigator's judgment

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Humedix Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Beom Joon Kim, M.D.

Role: STUDY_DIRECTOR

Dermatology

Locations

Chung-Ang University Hospital

Seoul, Heukseok-ro, Dongjak-gu, South Korea

Countries

South Korea

Other Identifiers

HMM1-022

Identifier Type: -

Identifier Source: org_study_id